Project Details
Description
Glioblastoma (GBM) is a deadly brain cancer with a current survival of only 15 months despite standard of care.
Immunotherapy, which utilizes the body’s own immune system to target the cancer, is a promising new approach to treating
GBM that has shown significant efficacy in many other cancer types. The utilization of B cells as an immunotherapy is a novel
approach, and we previously showed our B cell based vaccine (Bvax) can confer a very potent survival benefit in preclinical
GBM models. The goal of this study is to investigate the underlying mechanisms of our B cell vaccine to both improve our
current vaccine as well as develop novel immunotherapy strategies against GBM.
Status | Finished |
---|---|
Effective start/end date | 6/1/22 → 8/31/22 |
Funding
- American Brain Tumor Association (MSSF2200050)
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.